Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
June 03, 2021 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease
June 02, 2021 07:00 ET
|
Nurix Therapeutics, Inc.
Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IMiD activity Data were presented at the European Alliance of Associations for Rheumatology (EULAR)...
Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress
May 21, 2021 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical...
Arvinas to Present at the UBS Global Healthcare Virtual Conference
May 20, 2021 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
May 11, 2021 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that members of...
Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven
May 04, 2021 14:52 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 04, 2021 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
April 13, 2021 16:01 ET
|
Nurix Therapeutics, Inc.
On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong financial position after...
Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
April 05, 2021 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...